Dr. Daruka Mahadevan, MD, PhD
Claim this profileMays Cancer Center
Studies Solid Tumors
Studies Uterine Tumors
10 reported clinical trials
12 drugs studied
Area of expertise
1Solid Tumors
Stage IV
Stage III
MSI-low positive
2Uterine Tumors
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Daruka Mahadevan, MD, PhD is currently running
Pembrolizumab + Gemcitabine
for Bladder Cancer
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the patient's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding pembrolizumab to gemcitabine may delay the return of BCG-unresponsive bladder cancer for longer period compared to gemcitabine alone.
Recruiting1 award Phase 223 criteria
LNCB74
for Cancer
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
Recruiting1 award Phase 15 criteria
More about Daruka Mahadevan, MD, PhD
Clinical Trial Related2 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Daruka Mahadevan, MD, PhD has experience with
- Pembrolizumab
- SM08502
- PRJ1-3024
- DT2216
- Docetaxel
- Abiraterone
Breakdown of trials Daruka Mahadevan, MD, PhD has run
Uterine Tumors
Lung Cancer
Skin Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daruka Mahadevan, MD, PhD specialize in?
Daruka Mahadevan, MD, PhD focuses on Solid Tumors and Uterine Tumors. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is Daruka Mahadevan, MD, PhD currently recruiting for clinical trials?
Yes, Daruka Mahadevan, MD, PhD is currently recruiting for 3 clinical trials in San Antonio Texas. If you're interested in participating, you should apply.
Are there any treatments that Daruka Mahadevan, MD, PhD has studied deeply?
Yes, Daruka Mahadevan, MD, PhD has studied treatments such as Pembrolizumab, SM08502, PRJ1-3024.
What is the best way to schedule an appointment with Daruka Mahadevan, MD, PhD?
Apply for one of the trials that Daruka Mahadevan, MD, PhD is conducting.
What is the office address of Daruka Mahadevan, MD, PhD?
The office of Daruka Mahadevan, MD, PhD is located at: Mays Cancer Center, San Antonio, Texas 78229 United States. This is the address for their practice at the Mays Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.